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Nowadays, personalized medicine is considered to be of
utmost importance to target the different causes of identical
phenotypes.
[1–5] For example, cancer of the same type can sig-
nificantly differ in its biochemical phenotypes and thus its mo-
lecular profile between patients. The disease-specific character-
ization of malignant cells at the molecular level is a prerequi-
site for targeted therapy and personalized treatment. Positron
emission tomography (PET) and its combination with comput-
er tomography (PET/CT) and magnetic resonance tomography
(PET/MRT) in modern hybrid systems offer the possibility to lo-
calize and quantify biochemical function by means of PET with
anatomical (CT) and morphological (MRT) information. For this
purpose, radiolabeled probes are used that target, for example,
enzyme activities, transport systems, and surface receptors
with high affinity and specificity.
[6–8] We describe the develop-
ment of the first gallium-68 (t1/2=68 min) ligand for the G-pro-
tein-coupled receptor CXCR4 and preliminary demonstrate its
potential for in vivo imaging of CXCR4 expression using a
mouse model with a human small-cell lung cancer xenograft.
This ligand offers the possibility to be used as an initial tool for
diagnosis in an approach of personalized medicine for treating
CXCR4-related cancer.
The chemokine receptor subtype CXCR4 is an attractive
target for cancer diagnosis and treatment as it is overex-
pressed on more than 70% of human solid tumors, including
mammary cancer, prostate cancer, B-cell lymphoma, neuroblas-
toma, melanoma, cervical adenocarcinoma, and glioma,
among others.
[9] Moreover, it is involved in three fundamental
aspects of cancer: primary tumor growth, cancer cell migra-
tion, and establishment of metastatic sites; and therefore, it
can be considered an ideal target. Being also a coreceptor for
the cellular entry of the HIV, many peptidic and nonpeptidic li-
gands with different modes of antagonistic activity have been
developed.
[10–18] These highly CXCR4-specific agents can serve
for the introduction of PET-active prosthetic groups. This ap-
proach is often complicated by loss of binding affinity, unde-
sired alteration of biodistribution and instability in vivo.
[19,20] A
careful optimization of many molecular parameters is necessa-
ry to develop a suitable tracer for diagnostic application.
As a starting point for the development of the first
68Ga-la-
beled, CXCR4-directed PET probe, we used cyclic pentapeptide
1a (Figure 1) developed by Fujii et al. and the later published
analogue 1b, as it is an inverse agonist of CXCR4.
[21–23] Small,
cyclic peptides such as these should exhibit high in vivo stabili-
ty towards enzymatic degradation, especially as they contain
d-amino acids and N-methylated peptide bonds.
[6] Although al-
lowing first positive imaging experiments, radioiodination of
the tyrosine residue increased the lipophilicity and turned out
to be unsuccessful for our purpose. Consequently, we investi-
gated the introduction of more hydrophilic groups and fo-
cused on the (radio)metal chelator 1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid (DOTA) because it can be used in
combination with the corresponding radiometals for different
imaging techniques like PET (e.g.,
68Ga
3+), single photon emis-
sion tomography (SPECT; e.g.,
111In
3+), or magnetic resonance
imaging (MRI; e.g., Gd
3+,F e
3+) and also for radionuclide thera-
py (e.g.,
177Lu
3+,
90Y
3+).
Previous studies of our group and others have shown that
all side chains of peptides 1aand 1bcontribute to binding af-
finity. An attempt to remove the side chain of Arg3 to intro-
duce anchoring functions in this position resulted in a total
loss of activity, whereas substitution of Arg2 by ornithine (Orn)
and its acylated derivatives gave a reduction of only one order
of magnitude. Unfortunately, introduction of larger acyl or alkyl
substituents on Orn2 also strongly reduced the affinity (for de-
tails see Supporting Information).
[24] Unexpectedly, ligands with
benzoic acids attached to the Orn2 side chain retained most
Figure 1. CXCR4 ligands modified to introduce radioisotopes.
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Table 1).
[25]
An important affinity improvement was achieved by starting
from peptide 1b, which differs from 1a by an d-arginine resi-
due instead of l-arginine in position 2 and simultaneous N-
methylation of the peptide bond between d-Tyr1-d-Arg2. We
chose DOTA as a complexing moiety as its cyclen scaffold is
also found in the CXCR4 drug AMD3100 (Mozobil
TM), and we
hypothesized that we could gain receptor affinity as chelates
of AMD3100 have shown to have superior affinity.
[26] To attach
DOTA, the d-arginine group was again substituted by d-Orn.
The type and length of spacer between the peptide and DOTA
was optimized in more than 25 compounds (see Supporting
Information) to yield the highest affinity compounds 2a–c
(Figure 2 and Table 1). Receptor affinities also depend on the
chelation state as well as the type and radii of the metal ion in
the complexing moiety.
[27–29] Therefore, we tested gallium and
indium compounds as they are relevant for imaging purposes
and have different ionic radii. While the binding affinities for
the free DOTA compound 2a and its indium chelate 2b are
150 nm and 444n m, respectively, the gallium complex exhib-
ited an affinity of 51n m, which is virtually identical with the
unmodified peptides 1aand 1b.
In vivo testing of [
68Ga]2c was carried out in nude mice
bearing OH-1 human small-cell lung cancer xenografts. The
68Ga-labeled ligand accumulated in high levels in CXCR4-ex-
pressing tumors and allowed for a high contrasting functional
imaging of the CXCR4 receptor status in vivo (Figure 3). Co-
injection of 50 mg cyclo-(-d-Tyr1-Arg2-Arg3-Nal4-Gly5) or
AMD3100 (data not shown) per mouse significantly reduced
the tumor uptake, thus demonstrating specificity of CXCR4-
mediated tumor binding or [
68Ga]2c.
Quantitative biodistribution data 60 and 120 min post-injec-
tion of [
68Ga]2c alone or in the presence of 50 mg competitor
are summarized in Table 2. High tumor to organ ratios were
observed already 1 h post-injection. Furthermore, the results
Table 1. IC50 values for the tested CXCR4 ligands.
Compd IC50
[a] [nm] Compd IC50
[a] [nm]
1a 4.31.2
[b] 2a 150
1b 22 2b 444
1c 91 2c 51
1d 223
[a] Values represent the meanSD of three experiments except where
values greater than 100 nm were measured. [b] Value taken from Refer-
ence [15].
Figure 2. Structures of the best DOTA peptides for imaging. The DOTA
moiety is depicted simplified and not representing the actual state of metal
ion coordination.
Figure 3. a) PET summation images (90–110 min p.i.) of OH1 h-SCLC tumor-
bearing nude mice using [
68Ga]2c(tracer-only study, injected dose: 230 mCi);
b) Competition by co-injection of 50 mg cyclo-(d-Tyr1-Arg2-Arg3-Nal4-Gly5)
per mouse (injected dose: 300 mCi). The radioactivity scales have been nor-
malized according the injected activity of each mouse.
Table 2. Biodistribution and tumor/muscle ratios of [
68Ga]2cin OH1 mice
at 1 h and 2 h post-injection (p.i.).
Organ Biodistribution
[a] [%IDg
1] Blockade
[b]
1 h p.i. (n=8) 2 h p.i. (n=3) 1 h p.i. (n=4)
Blood 1.080.27 0.580.14 2.500.64
Heart 0.600.16 0.290.10 1.380.52
Lung 1.410.26 2.852.69 3.251.06
Liver 1.850.24 1.480.31 2.270.59
Pancreas 0.300.07 0.210.02 0.750.19
Spleen 0.690.09 0.650.25 1.030.40
Kidney 3.060.63 2.070.46 7.191.83
Adrenal glands 0.830.55 0.500.15 0.870.32
Stomach 0.720.26 0.460.12 1.400.30
Intestine 0.450.11 0.360.04 1.000.32
Muscle 0.380.09 0.280.17 0.580.21
Tumor 6.161.16 4.631.54 1.880.30
Tumor/Muscle 16.553.84 18.497.29 3.451.45
[a] Data are given as the injected dose (%) per gram of tissue and repre-
sent the meanSD of n=8, 3 and 4 (see above) experiments. [b] Deter-
mined in the presence of 50 mg cyclo-(d-Tyr1-Arg2-Arg3-Nal4-Gly5). All
animal experiments were approved by local authorities and are in compli-
ance with the institutions guidelines.
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MEDfrom the classical biodistribution study confirm distribution
and specificity of tracer accumulation as observed by the PET
imaging study.
[
68Ga]2c is the first
68Ga-labeled CXCR4 imaging probe and
shows excellent in vivo distribution and binding characteristics.
The overexpression of CXCR4 in a variety of tumors and its
role in organ-specific metastasis recommend the further clini-
cal evaluation of [
68Ga]2c. This study paves the way for molec-
ular imaging of this important GPCR in animals and man to
enable personalized medicine and individualized treatment.
Furthermore, chelates of 2a with therapeutic nuclides are an
obvious choice for possible future endo-radiotherapeutic
approaches.
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